tradingkey.logo

CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene Grenadenorepvec

ReutersApr 26, 2025 8:12 PM

- CG Oncology Inc CGON.O:

  • CG ONCOLOGY ANNOUNCES BEST-IN-DISEASE DURABILITY DATA IN BOND-003 COHORT C AND PROMISING EARLY SIGNAL IN COHORT P FOR CRETOSTIMOGENE GRENADENOREPVEC AT THE AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING

  • CG ONCOLOGY INC - CRETOSTIMOGENE MONOTHERAPY SHOWS 42.3% RESPONSE RATE AT 24 MONTHS

  • CG ONCOLOGY INC - 58.3% PATIENTS SHOW DURABLE RESPONSE AT 24 MONTHS

  • CG ONCOLOGY INC - 97.3% PATIENTS FREE FROM MIBC PROGRESSION AT 24 MONTHS

  • CG ONCOLOGY INC - 91.6% RESPONDERS CYSTECTOMY-FREE AT 24 MONTHS

  • CG ONCOLOGY INC - NO GRADE 3 OR GREATER ADVERSE EVENTS REPORTED

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI